Two Sigma Advisers
VRNA

Two Sigma Advisers’s Verona Pharma VRNA Stock Holding History

Two Sigma Advisers’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,600
Closed -$1.29M – 2655
2025
Q2 		$1.29M Buy
+13,600
New +$1.01M ﹤0.01% 1319
2025
Q1 		– Sell
-19,000
Closed -$882K – 2596
2024
Q4 		$882K Buy
+19,000
New +$713K ﹤0.01% 1519
2023
Q4 		– Sell
-47,800
Closed -$779K – 2657
2023
Q3 		$779K Sell
47,800
-240,483
-83% -$4.63M ﹤0.01% 1624
2023
Q2 		$6.09M Buy
288,283
+25,483
+10% +$543K 0.02% 679
2023
Q1 		$5.28M Buy
262,800
+43,200
+20% +$933K 0.01% 785
2022
Q4 		$5.74M Buy
219,600
+66,200
+43% +$882K 0.02% 734
2022
Q3 		$1.57M Buy
+153,400
New +$1.29M ﹤0.01% 1299

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Advisers's VRNA Position: Q3 2025 in Review

Two Sigma Advisers sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 13,600 shares — an estimated $1.29M sold.

Two Sigma Advisers first reported a position in VRNA in Q3 2022 and held it in 7 quarters. The position peaked at $6.09M in Q2 2023. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Two Sigma Advisers reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 13,600 Verona Pharma shares in Q3 2025, an estimated $1.29M.
  • Two Sigma Advisers first reported a position in Verona Pharma in Q3 2022 and held it in 7 quarters.
  • Two Sigma Advisers's Verona Pharma position peaked at $6.09M in Q2 2023.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.